Detalles de la búsqueda
1.
A Multicenter Assessment of the Outcomes and Toxicities of Foscarnet for Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex in Immunocompromised Patients.
Open Forum Infect Dis
; 11(3): ofae046, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38444818
2.
Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections.
J Med Chem
; 65(20): 13614-13628, 2022 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36202389
3.
Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
Int J Infect Dis
; 10(2): 136-47, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16183318
4.
Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization.
Chest
; 128(4): 1980-8, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16236845
5.
Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.
Clin Drug Investig
; 35(5): 307-17, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25813217
6.
Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections.
J Infect
; 49(2): 115-25, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15236918
7.
Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae.
J Infect
; 51(3): 201-5, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16230216
Resultados
1 -
7
de 7
1
Próxima >
>>